Niagen Bioscience (NAGE) Q4 2025 earnings review
Profitability Secured, But Top-Line Momentum is Decelerating Rapidly
Niagen Bioscience successfully transitioned into a highly profitable, cash-generating business in 2025, culminating in $129.4M in annual revenue and $17.4M in net income. However, the hyper-growth narrative is cracking. Despite management highlighting a 30% full-year sales increase, Q4 YoY growth collapsed to 16%—less than half the growth rate seen in Q1. Furthermore, FY26 guidance projects a muted 10-15% top-line expansion. While gross margins are stellar and the balance sheet is pristine with $64.8M in cash, investors must now value NAGE as a maturing, steady-growth consumer health company rather than a high-flying disruptor.
🐂 Bull Case
Gross margins expanded 250 bps in FY25 to 64.3%, and the company generated $13.5M in operating cash flow. The business model is highly scalable and structurally profitable.
The acquisition of the Queen's University Belfast patent portfolio gives Niagen sole ownership of foundational NR IP, shielding it from generic competition and opening lucrative pharmaceutical licensing avenues.
🐻 Bear Case
The deceleration is stark. Revenue growth dropped from 38% YoY in Q1 to 16% in Q4. FY26 guidance of 10-15% implies the easiest market share gains have already been harvested.
General and Administrative expenses surged $6.4M in Q4 YoY. Management is guiding for another $4.0-$5.0M increase in FY26, threatening to compress operating leverage if sales don't re-accelerate.
⚖️ Verdict: ⚪
Neutral. The financial foundation is undeniably stronger with zero debt and robust cash flow, but the sharp deceleration in the growth rate and stagnant B2B ingredient sales cap the near-term upside.
Key Themes
E-Commerce Anchors the Business
The direct-to-consumer Tru Niagen business remains the most reliable growth engine. E-commerce revenue has shown a stable, sequential climb throughout the year, reaching $20.2M in Q4 (up from $17.3M in 24Q4). This channel now represents 60% of total company revenue and provides predictable, high-margin cash flow.
Ingredient Segment Reversing
A major data point contradicting the company's positive growth narrative is the stalling Niagen Ingredients business. After surging to $8.0M in 25Q1, ingredient sales have sequentially declined every quarter, hitting $5.6M in Q4. Furthermore, the heavily touted pharmaceutical-grade Niagen generated only $0.9M in Q4, indicating the clinic rollout is failing to gain meaningful volume traction.
IP Consolidation Opens Strategic Doors
The December 2025 acquisition of the core NR patent portfolio from Queen’s University Belfast is a masterstroke. It grants Niagen sole ownership of the composition-of-matter IP. Not only did this trigger an immediate $2.0M royalty settlement gain in Q4, but it dramatically increases their leverage in fighting off cheap knockoffs and negotiating future pharmaceutical partnerships.
Operating Expenses Outpacing Q4 Growth
Q4 Operating Expenses surged 59% YoY to $17.6M. While the prior year benefited from $4.8M in one-time legal/royalty reversals, core SG&A is undeniably expanding. S&M and R&D grew by $1.7M and $0.4M respectively in Q4. Management must prove they can scale the top line to justify this heavier cost structure.
Macro Adaptation: HSA/FSA Integration
In response to a tighter consumer spending environment, the company wisely partnered with Truemed in January 2026. This allows US customers to use pre-tax HSA/FSA funds for Tru Niagen purchases via a Letter of Medical Necessity. This macro-level pivot effectively lowers the consumer's out-of-pocket cost and could significantly boost subscription retention rates.
Other KPIs
Stable. Up 160 bps from 62.5% in 24Q4. The company successfully maintained the mid-60s margin profile established earlier in the year, driven by favorable product mix and better overhead utilization. This structurally higher margin floor is a key pillar of the company's profitability.
Accelerating. The balance sheet is a fortress. Cash grew from $44.7M at the end of 2024 to $64.8M, with zero debt. This allows ample runway to internally fund pharmaceutical trials or execute share buybacks without tapping equity markets.
Decelerating. Down from $7.2M in the prior year quarter. While technically a YoY decline, this was heavily distorted by a $3.5M royalty reversal and a $1.3M credit loss recovery in 24Q4. Adjusted EBITDA, which strips out some noise, actually increased by $0.7M YoY to $4.1M.
Guidance
Decelerating. This excludes the recently sold Analytical Reference Standards segment (which generated ~$3.1M in 2025). The implied midpoint of 12.5% is a significant step down from the 30% growth achieved in FY25, signaling that the post-pandemic, post-NMN-ban demand surge has normalized.
Stable. The company expects to edge slightly higher than the 64.3% achieved in FY25. Inventory cost improvements and continued scaling of the direct-to-consumer mix are expected to offset any pricing pressures.
Accelerating. Overhead continues to climb. Management attributes this to infrastructure investments, legal expenses for market expansion, and increased share-based compensation.
Key Questions
Drivers of Deceleration
Your FY26 revenue guidance implies a growth rate of 10-15%, less than half of what was achieved in FY25. Is this conservatism, or are we seeing a structural plateau in the core consumer base for NAD+ precursors?
Pharma-Grade Niagen Traction
Pharmaceutical-grade Niagen sales were just $0.9M in Q4, virtually flat from earlier in the year despite the highly anticipated clinic rollout. What are the specific bottlenecks preventing broader adoption, and when should we expect this segment to materially impact the top line?
Licensing Strategy Post-IP Acquisition
Following the acquisition of the core NR patent portfolio from Queen’s University, how will your IP enforcement and outbound licensing strategy change? Should we expect more settlement gains or recurring royalty streams in FY26?